October 23, 2018
FDA: Class I recall of Endologix AFX Endovascular AAA System
Editor's Note
The Food & Drug Administration on October 15 classified the recall by Endologix, Inc, of its AFX Endovascular AAA System as Class I, the most serious.
The recall was initiated because of the risk of Type III endoleaks. When a Type III endoleak occurs, blood continues to flow into the aneurysm, increasing the likelihood of serious injury, rupture, or death.
Free Daily News
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement